Unique IL-13Rα2-based HIV-1 vaccine strategy to enhance mucosal immunity, CD8 + T-cell avidity and protective immunity

Mucosal Immunology

Volumn 6, Issue 6, 2013, Pages 1068-1080

  Ranasinghe, C ^a   Trivedi, S ^a   Stambas, J ^a,b,c   Jackson, R J ^a  

^a Australian National University   (Australia)

^b DEAKIN UNIVERSITY   (Australia)

^c CSIRO   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CHEMOKINE; CYTOKINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 13 RECEPTOR ALPHA2; RECOMBINANT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DRUG BINDING SITE; FEMALE; GENE CONSTRUCT; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPHOCYTE FUNCTION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PEYER PATCH; PRIORITY JOURNAL; RESPIRATORY TRACT MUCOSA; T LYMPHOCYTE SUBPOPULATION; VIRAL GENE DELIVERY SYSTEM; WILD TYPE;

AIDS VACCINES; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, MUCOSAL; INTERLEUKIN-13; LUNG; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MUTANT PROTEINS; PROTEIN ENGINEERING; RECEPTORS, INTERLEUKIN-13;

EID: 84883598341     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2013.1     Document Type: Article

References (53)

1. Veazey, R.S. et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 280, 427-431 (1998).
2. Shacklett, B.L., Shacklett, B.L., Critchfield, J.W., Ferre, A.L. & Hayes, T.L. Mucosal immunity to HIV: A review of recent literature. Mucosal T-cell responses to HIV: Responding at the front lines. Curr Opin HIV AIDS 3, 541-547 (2008).
3. Ahlers, J.D. & Belyakov, I.M. Strategies for optimizing targeting and delivery of mucosal HIV vaccines. Eur J Immunol 39, 2657-2669 (2009).
4. Corbett, M. et al. Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic. Proc Natl Acad Sci USA 105, 2046-2051 (2008).
5. Alexander-Miller, M.A., Leggatt, G.R., Sarin, A. & Berzofsky, J.A. Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J Exp Med 184, 485-492 (1996).
6. Alexander-Miller, M.A. High-Avidity CD8+ T cells: Optimal soldiers in the war against viruses and tumors. Immunol Res 31, 13-24 (2005).
7. Belyakov, I.M. et al. Impact of vaccine-induced mucosal high-Avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa. Blood 107, 3258-3264 (2006).
8. Ranasinghe, C. et al. Mucosal HIV-1 pox virus prime-boost immunization Induces high-Avidity CD8+ T cells with regime-dependent cytokine/ granzyme B profiles. J Immunol 178, 2370-2379 (2007).
9. Kent, S.J. et al. Mucosally-Administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication inmacaques following vaginal challenge with CCR5-Tropic SHIV(SF162P3). Vaccine 23, 5009-5021 (2005).
10. Ranasinghe, C. & Ramshaw, I.A. Immunisation route-dependent expression of IL-4/IL-13 can modulate HIV-specific CD8(+) CTL avidity. Eur J Immunol 39, 1819-1830 (2009).
11. Takeda, K., Kamanaka, M., Tanaka, T., Kishimoto, T. & Akira, S. Impaired IL-13-mediated functions of macrophages in STAT6-deficient mice. J Immunol 157, 3220-3222 (1996).
12. Tabata, Y. & Khurana Hershey, G.K. IL-13 receptor isoforms: Breaking through the complexity. Curr Allergy Asthma Rep 7, 338-345 (2007).
13. Chen, W. et al. IL-13R alpha 2 membrane and soluble isoforms differ in humans and mice. J Immunol 183, 7870-7876 (2009).
14. Fichtner-Feigl, S., Strober, W., Kawakami, K., Puri, R.K. & Kitani, A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGFbeta1 production and fibrosis. Nat Med 12, 99-106 (2006).
15. Fujisawa, T., Joshi, B.H. & Puri., R.K. IL-13 regulates cancer invasion and metastasis through IL-13Ralpha2 via ERK/AP-1 pathway in mouse model of human ovarian cancer. Int J Cancer 131, 344-356 (2012).
16. Ranasinghe, C. et al. A comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/rFPV and poxvirus-poxvirus prime boost immunisations. Vaccine 29, 3008-3020 (2011).
17. Ranasinghe, C. et al. Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1. Vaccine 24, 5881-5895 (2006).
18. Kroger, C.J., Amoah, S. & Alexander-Miller, M.A. Cutting edge: Dendritic cells prime a high avidity CTL response independent of the level of presented antigen. J Immunol 180, 5784-5788 (2008).
19. Almeida, J.R. et al. Superior control of HIV-1 replication by CD8+ Tcells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 204, 2473-2485 (2007).
20. Harari, A. et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting Tcell responses. J Exp Med 205, 63-77 (2008).
21. Burgers,W.A. et al. Broad, high-magnitude and multifunctional CD4+ and CD8+ T-cell responses elicited by a DNA and modified vaccinia Ankara vaccine containing human immunodeficiency virus type 1 subtypeCgenes in baboons. J Gen Virol 90, 468-480 (2009).
22. Mothe, B. et al. CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control. PLoS One 7, e29717 (2012).
23. Berger, C.T. et al. High-functional-Avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control. J Virol 85, 9334-9345 (2011).
24. Gherardi, M.M., Ramirez, J.C. & Esteban, M. Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: Suppressive effects of IL-12 boost are mediated by nitric oxide. J Virol 74, 6278-6286 (2000).
25. Dale, C.J. et al. Evaluation inmacaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFNgamma or IL-12. Vaccine 23, 188-197 (2004).
26. Harrison, J.M. et al. 4-1BBL coexpression enhances HIV-specific CD8 T cell memory in a poxvirus prime-boost vaccine. Vaccine 24, 6867-6874 (2006).
27. Day, S.L., Ramshaw, I.A., Ramsay, A.J. & Ranasinghe, C. Differential effects of the type I interferons alpha4, beta, and epsilon on antiviral activity and vaccine efficacy. J Immunol 180, 7158-7166 (2008).
28. Xi, Y., Day, S.L., Jackson, R.J. & Ranasinghe, C. Role of novel type I interferon epsilon (IFN-e) in viral infection and mucosal immunity. Mucosal Immunol 5, 610-622 (2012).
29. Wijesundara, D.K., Tscharke, D.C., Jackson, R.J. & Ranasinghe, C. Reduced interleukin-4 receptor a expression on CD8+ T cells correlates with high quality anti-viral immunity. PLoS One (in press).
30. Khodoun, M. et al. Differences in expression, affinity, and function of soluble (s)IL-4Ralpha and sIL-13Ralpha2 suggest opposite effects on allergic responses. J Immunol 179, 6429-6438 (2007).
31. de Weerd, N.A. & Nguyen, T. The interferons and their receptorsdistribution and regulation. Immunol Cell Biol 1038, 9 (2012).
32. Kasaian, M.T. et al. IL-13 antibodies influence IL-13 clearance in humans by modulating scavenger activity of IL-13Ralpha2. J Immunol 187, 561-569 (2011).
33. Stoklasek, T.A.,Colpitts, S.L., Smilowitz, H.M. & Lefrancois, L.MHCclass I and TCR avidity control the CD8 T cell response to IL-15/IL-15Ralpha complex. J Immunol 185, 6857-6865 (2010).
34. Perrigoue, J.G., Zaph, C., Guild, K., Du, Y. & Artis, D. IL-31-IL-31R interactions limit the magnitude of Th2 cytokine-dependent immunity and inflammation following intestinal helminth infection. J Immunol 182, 6088-6094 (2009).
35. Costa, D.L. et al. BALB/cmice infected with antimony treatment refractory isolate of Leishmania braziliensis present severe lesions due to IL-4 production. PLoS One 5, e965 (2011).
36. Liu, L. et al. Vaccinia virus induces strong immunoregulatory cytokine production in healthy human epidermal keratinocytes: A novel strategy for immune evasion. J Virol 79, 7363-7370 (2005).
37. Imrie, A. et al. Differential functional avidity of dengue virus-specific T-cell clones for variant peptides representing heterologous and previously encountered serotypes. J Virol 81, 10081-10091 (2007).
38. Maggi, E. et al. Th2-like CD8+ T cells showing B cell helper function and reduced cytolytic activity in human immunodeficiency virus type 1 infection. J Exp Med 180, 489-495 (1994).
39. Kienzle, N., Baz, A. & Kelso, A. Profiling the CD8low phenotype, an alternative career choice for CD8 T cells during primary differentiation. Immunol Cell Biol 82, 75-83 (2004).
40. Ahlers, J.D. et al. A push-pull approach to maximize vaccine efficacy: Abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L. Proc Natl Acad Sci USA 99, 13020-13025 (2002).
41. Hahn, C. et al. Inhibition of the IL-4/IL-13 receptor system prevents allergic sensitization without affecting established allergy in a mouse model for allergic asthma. J Allergy Clin Immunol 111, 1361-1369 (2003).
42. Morimoto, M. et al. IL-13 receptor alpha2 regulates the immune and functional response to Nippostrongylus brasiliensis infection. J Immunol 183, 1934-1939 (2009).
43. Bree, A. et al. IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys. J Allergy Clin Immunol 119, 1251-1257 (2007).
44. Zheng, T. et al. IL-13 receptor alpha2 selectively inhibits IL-13-induced responses in the murine lung. J Immunol 180, 522-529 (2008).
45. Takenouchi, M. et al. Epigenetic modulation enhances the therapeutic effect of anti-IL-13R(alpha)2 antibody in human mesothelioma xenografts. Clin Cancer Res 17, 2819-2829 (2011).
46. Joshi, B.H., Leland, P., Calvo, A., Green, J.E. & Puri, R.K. Human adrenomedullin up-regulates interleukin-13 receptor alpha2 chain in prostate cancer in vitro and in vivo: A novel approach to sensitize prostate cancer to anticancer therapy. Cancer Res 68, 9311-9317 (2008).
47. Tabata, Y. et al. Allergy-driven alternative splicing of IL-13 receptor alpha2 yields distinct membrane and soluble forms. J Immunol 177, 7905-7912 (2006).
48. Boyle, D.B. & Coupar, B.E. Construction of recombinant fowlpox viruses as vectors for poultry vaccines. Virus Res 10, 343-356 (1988).
49. Heine, H.G. & Boyle, D.B. Infectious bursal disease virus structural protein VP2 expressed by a fowlpox virus recombinant confers protection against disease in chickens. Arch Virol 131, 277-292 (1993).
50. Coupar, B.E., Andrew, M.E. & Boyle, D.B. A general method for the construction of recombinant vaccinia viruses expressing multiple foreign genes. Gene 68, 1-10 (1988).
51. Coupar, B.E.H. et al. Fowlpox virus vaccines for HIV and SIV clinical and pre-clinical trials. Vaccine 24, 1378-1388 (2006).
52. Cukalac, T. et al. Narrowed TCR diversity for immunised mice challenged with recombinant influenza A-HIV Env(311-320) virus. Vaccine 27, 6755-6761 (2009).
53. Sexton, A. et al. Evaluation of recombinant influenza virus-simian immunodeficiency virus vaccines in macaques. J Virol 83, 7619-7628 (2009).